Drugs in Dev.
Pulmonary/Respiratory Diseases
Phase II/ Phase III
France 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $6.8 million
Deal Type : Private Placement
Biophytis Announces a € 6.1 Million Capital Increase Through Private Placement
Details : Net proceeds of the private placement will be used primarily to progress Biophytis drug development programs, including the COVA clinical study, To begin Sarconeos (BIO101) Phase 2/3 clinical trial as a potential treatment for respiratory failure associa...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 03, 2020
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $6.8 million
Deal Type : Private Placement
